HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed October 17, 2017.
   Google Scholar
• European AIDS Clinical Society. EACS Guidelines Version 9.0; October 2017.
   Google Scholar
• De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314–2321.
   PubMed Web of Science ®Google Scholar
• Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81(24):13845–13851.
   PubMed Web of Science ®Google Scholar
• Lathouwers E, Gupta S, Haddad M, Paquet A, De Meyer S, Baugh B. Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012. AIDS Res Hum Retroviruses. 2015;31(6):628–635.
   PubMed Web of Science ®Google Scholar
• Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14(1):49–59.
   PubMed Web of Science ®Google Scholar
• Mills A, Crofoot G Jr, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439–445.
   PubMed Web of Science ®Google Scholar
• Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.
   PubMed Web of Science ®Google Scholar
• Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929–939.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, Brinson C, Ramgopal M, et al. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects. HIV Med. 2015;16(5):288–296.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012;13(7):398–405.
   PubMed Web of Science ®Google Scholar
• Girard PM, Antinori A, Arribas JR, et al. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. HIV Med. 2017;18(1):5–12.
   PubMed Web of Science ®Google Scholar
• PREZISTA^® (darunavir) [package insert]. Titusville, NJ: Janssen Therapeutics; 2016.
   Google Scholar
• De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24(3):379–388.
   PubMed Web of Science ®Google Scholar
• De Meyer S, Dierynck I, Lathouwers E, et al. Identification of mutations predictive of a diminished response to darunavir/ritonavir (refined profile): analysis of data from treatment-experienced subjects in POWER 1, 2, 3 and DUET-1 and DUET-2. Presented at: 6th European HIV Drug Resistance Workshop. Budapest; March 26–28, 2008. Abstract 54.
   Google Scholar
• Wensing AM, Calvez V, Gunthard HF, et al. 2017 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2017;24(4):132–141.
   PubMedGoogle Scholar
• Lathouwers E, De La Rosa G, Van de Casteele T, et al. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients. Antivir Ther. 2013;18(3):289–300.
   PubMed Web of Science ®Google Scholar
• Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365–2374.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Zona S, Cossarizza A, et al. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial. Int J STD AIDS. 2014;25(3):207–212.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard PM, Paton N, et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 2016;17(5):358–367.
   PubMed Web of Science ®Google Scholar
• Paton NI, Stohr W, Arenas-Pinto A, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015;2(10):e417–426.
   PubMed Web of Science ®Google Scholar
• Gianotti N, Galli L, Maserati R, et al. Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). New Microbiol. 2016;39(4):290–294.
   PubMed Web of Science ®Google Scholar
• Gianotti N, Cozzi-Lepri A, Antinori A, et al. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One. 2017;12(2):e0171611.
   PubMed Web of Science ®Google Scholar
• Santos JR, Llibre JM, Bravo I, et al. Short communication: efficacy and safety of treatment simplification to lopinavir/ritonavir or darunavir/ritonavir monotherapy: A randomized clinical trial. AIDS Res Hum Retroviruses. 2016;32(5):452–455.
   PubMed Web of Science ®Google Scholar
• Wijting IEA, Rokx C, Boucher CAB, et al. Dolutegravir as maintenance monotherapy for HIV-1: a randomized clinical trial. Presented at: the Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA; February 13–16, 2017. Abstract 451LB.
   Google Scholar
• Blanco JL, Oldenbuette C, Thomas R, et al. Pathways of resistance in subjects failing dolutegravir monotherapy. Presented at: the Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA; February 13–16, 2017. Abstract 42.
   Google Scholar
• Brown K, Stewart L, Whitcomb JM, Yang D, Nettles RE, Lathouwers E. Prevalence of darunavir resistance in the United States (2010–2015). Presented at: 9th International AIDS Society (IAS) Conference. Paris; July 23–26, 2017. Poster TUPEB0372.
   Google Scholar
• Orkin C, Molina J-M, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2017. Epub ahead of print. doi: 10.1016/S2352-3018(17)30179-0
   Web of Science ®Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–455.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1–7.
   PubMed Web of Science ®Google Scholar
• World Health Organization. HIV Drug Resistance Surveillance Guidance: 2015 Update (Technical Update); 2015.
   Google Scholar
• Nachega JB, Marconi VC, van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167–174.
   PubMedGoogle Scholar
• Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr. 2014;65(5):587–596.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med. 2008;16(5):138–145.
   PubMedGoogle Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17(5):138–145.
   PubMedGoogle Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18(5):156–163.
   PubMedGoogle Scholar
• Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19(4):156–164.
   PubMedGoogle Scholar